O Shaughnessy Asset Management LLC Raises Stake in Cencora, Inc. (NYSE:COR)

O Shaughnessy Asset Management LLC increased its stake in Cencora, Inc. (NYSE:COR - Free Report) by 16.7% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 52,965 shares of the company's stock after acquiring an additional 7,597 shares during the quarter. O Shaughnessy Asset Management LLC's holdings in Cencora were worth $11,900,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. United Bank increased its stake in Cencora by 4.2% during the 3rd quarter. United Bank now owns 5,601 shares of the company's stock worth $1,261,000 after buying an additional 225 shares in the last quarter. Public Sector Pension Investment Board raised its stake in Cencora by 53.2% in the 3rd quarter. Public Sector Pension Investment Board now owns 6,908 shares of the company's stock valued at $1,555,000 after purchasing an additional 2,400 shares during the last quarter. Arete Wealth Advisors LLC lifted its holdings in Cencora by 4.9% in the 3rd quarter. Arete Wealth Advisors LLC now owns 2,412 shares of the company's stock valued at $541,000 after purchasing an additional 113 shares in the last quarter. Kestra Investment Management LLC grew its holdings in shares of Cencora by 39.0% during the third quarter. Kestra Investment Management LLC now owns 2,354 shares of the company's stock worth $530,000 after buying an additional 660 shares in the last quarter. Finally, Benjamin Edwards Inc. raised its position in shares of Cencora by 1,552.8% in the third quarter. Benjamin Edwards Inc. now owns 9,041 shares of the company's stock valued at $2,035,000 after buying an additional 8,494 shares during the last quarter. 97.52% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Cencora Trading Down 3.5 %

COR stock traded down $10.07 during mid-day trading on Friday, hitting $279.29. 4,404,535 shares of the company were exchanged, compared to its average volume of 1,469,415. Cencora, Inc. has a 12-month low of $214.77 and a 12-month high of $296.65. The firm has a market capitalization of $54.16 billion, a P/E ratio of 39.73, a PEG ratio of 1.31 and a beta of 0.51. The business has a fifty day simple moving average of $257.28 and a 200-day simple moving average of $242.65. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40.

Cencora (NYSE:COR - Get Free Report) last posted its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. On average, equities research analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Friday, February 14th were paid a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 0.79%. The ex-dividend date of this dividend was Friday, February 14th. Cencora's payout ratio is 31.29%.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on COR shares. Evercore ISI boosted their target price on Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a report on Thursday, February 6th. JPMorgan Chase & Co. raised their target price on Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a research note on Friday, January 24th. Wells Fargo & Company upped their price objective on shares of Cencora from $251.00 to $274.00 and gave the company an "equal weight" rating in a report on Friday, March 14th. Finally, StockNews.com raised shares of Cencora from a "hold" rating to a "buy" rating in a research note on Wednesday, March 12th. Two investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $280.20.

Insider Activity at Cencora

In other news, Chairman Steven H. Collis sold 14,578 shares of the company's stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $269.51, for a total transaction of $3,928,916.78. Following the sale, the chairman now owns 317,913 shares of the company's stock, valued at approximately $85,680,732.63. This represents a 4.38 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Silvana Battaglia sold 5,000 shares of Cencora stock in a transaction on Friday, February 21st. The shares were sold at an average price of $242.24, for a total value of $1,211,200.00. Following the completion of the transaction, the executive vice president now owns 15,374 shares of the company's stock, valued at approximately $3,724,197.76. This trade represents a 24.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 30,675 shares of company stock worth $8,034,778 in the last three months. 10.80% of the stock is owned by company insiders.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.